Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Parameswaran Hari MD

Interim Chief, Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center
Member of the Cardiovascular Center


Publications

  • Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation. (Kapke JT, Epperla N, Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2017 Jul;17(7):408-414 PMID: 28756899 08/02/2017
  • Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. (Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR) Biol Blood Marrow Transplant 2017 Jul 27 PMID: 28757436 08/02/2017
  • Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. (Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN) Am J Hematol 2017 Oct;92(10):E610-E611 PMID: 28699171 07/13/2017
  • Liver biopsy findings in patients with hematopoietic cell transplantation. (Eskandari F, Rowan DJ, Hari P, Kapke J, Schneidewend R, E Hagen C, Oshima K) Hum Pathol 2017 Aug;66:136-143 PMID: 28688898 07/10/2017
  • Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014. (D'Souza A, Zhang MJ, Huang J, Fei M, Pasquini M, Hamadani M, Hari P) Leukemia 2017 Sep;31(9):1998-2000 PMID: 28663578 PMCID: PMC5587375 07/01/2017
  • Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 06/21/2017
  • Recent advances in understanding multiple myeloma. (Hari P) Hematol Oncol Stem Cell Ther 2017 Jun 13 PMID: 28633036 06/21/2017
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. (Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM) Leukemia 2017 May 12 PMID: 28620163 06/18/2017
  • Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. (Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG) Br J Haematol 2017 Aug;178(4):571-582 PMID: 28485007 PMCID: PMC5574012 05/10/2017
  • PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 Jul 13;130(2):221-228 PMID: 28468799 PMCID: PMC5510790 05/05/2017
  • Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. (Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A) Cancer 2017 Aug 15;123(16):3141-3149 PMID: 28472539 PMCID: PMC5544566 05/05/2017
  • Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. (Hari P, Mateos MV, Abonour R, Knop S, Bensinger W, Ludwig H, Song K, Hajek R, Moreau P, Siegel DS, Feng S, Obreja M, Aggarwal SK, Iskander K, Goldschmidt H) Leukemia 2017 Apr 25 PMID: 28439109 04/26/2017
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 04/17/2017
  • Marizomib for central nervous system-multiple myeloma. (Badros A, Singh Z, Dhakal B, Kwok Y, MacLaren A, Richardson P, Trikha M, Hari P) Br J Haematol 2017 Apr;177(2):221-225 PMID: 28387460 04/08/2017
  • Evaluation of the Pharmacokinetics and Efficacy of a Busulfan Test Dose in Adult Patients Undergoing Myeloablative Hematopoietic Cell Transplantation. (Weil E, Zook F, Oxencis C, Canadeo A, Urmanski A, Waggoner M, Eastwood D, Pasquini M, Hamadani M, Hari P) Biol Blood Marrow Transplant 2017 Jun;23(6):952-957 PMID: 28288949 03/16/2017
  • Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. (Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M) Clin Lymphoma Myeloma Leuk 2017 May;17(5):305-311.e2 PMID: 28284742 03/13/2017
  • Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. (Garderet L, D'Souza A, Jacobs P, van Biezen A, Schönland S, Kroeger N, Morris C, Hari P) Biol Blood Marrow Transplant 2017 Jul;23(7):1193-1202 PMID: 28285082 03/13/2017
  • Disease burden of systemic light-chain amyloidosis: a systematic literature review. (Lin HM, Gao X, Cooke CE, Berg D, Labotka R, Faller DV, Seal B, Hari P) Curr Med Res Opin 2017 Jun;33(6):1017-1031 PMID: 28277869 03/10/2017
  • Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. (Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H) Biol Blood Marrow Transplant 2017 May;23(5):853-856 PMID: 28161608 PMCID: PMC5410937 02/06/2017
  • Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age. (Dhakal B, Nelson A, Guru Murthy GS, Fraser R, Eastwood D, Hamadani M, Pasquini M, D'Souza A, Hari P) Clin Lymphoma Myeloma Leuk 2017 Mar;17(3):165-172 PMID: 28159578 02/06/2017
  • Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. (Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C) Leuk Lymphoma 2017 Aug;58(8):1872-1879 PMID: 28140719 02/01/2017
  • PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction. (Guzman-Villanueva D, Migrino RQ, Truran S, Karamanova N, Franco DA, Burciu C, Senapati S, Nedelkov D, Hari P, Weissig V) J Liposome Res 2017 Feb 10:1-9 PMID: 28103719 PMCID: PMC5591079 01/21/2017
  • Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS) Hematol Oncol 2017 Jan 08 PMID: 28066928 01/10/2017
  • Instrumental variable with competing risk model. (Zheng C, Dai R, Hari PN, Zhang MJ) Stat Med 2017 Apr 15;36(8):1240-1255 PMID: 28064466 PMCID: PMC5479873 01/09/2017
  • Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. (Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, Lonial S) Clin Cancer Res 2017 Jul 01;23(13):3307-3315 PMID: 28053023 PMCID: PMC5496796 01/06/2017
  • Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. (Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Feb;23(2):269-277 PMID: 27864161 PMCID: PMC5346183 11/20/2016
  • Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. (Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P) Case Rep Hematol 2016;2016:2389038 PMID: 27843657 PMCID: PMC5097796 11/16/2016
  • HLA polymorphism and risk of multiple myeloma. (Beksac M, Gragert L, Fingerson S, Maiers M, Zhang MJ, Albrecht M, Zhong X, Cozen W, Dispenzieri A, Lonial S, Hari P) Leukemia 2016 Nov;30(11):2260-2264 PMID: 27461064 PMCID: PMC5134914 11/03/2016
  • Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. (Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 Jan;23(1):60-66 PMID: 27789362 PMCID: PMC5182098 10/30/2016
  • Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma. (Hari P, Raj RV, Olteanu H) N Engl J Med 2016 Oct 13;375(15):1501-1502 PMID: 27732828 10/13/2016
  • Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation. (Epperla N, Shah N, Hamadani M, Richardson K, Kapke JT, Patel A, Teegavarapu SP, Carrum G, Hari PN, Pingali SR, Karmali R, Fenske TS) Clin Lymphoma Myeloma Leuk 2016 Dec;16(12):672-678 PMID: 27660080 09/24/2016
  • Development of Novel Immunotherapies for Multiple Myeloma. (Al-Hujaily EM, Oldham RA, Hari P, Medin JA) Int J Mol Sci 2016 Sep 08;17(9) PMID: 27618026 PMCID: PMC5037783 09/13/2016
  • Recent advances in understanding multiple myeloma. (Dhakal B, Girnius S, Hari P) F1000Res 2016;5 PMID: 27610224 PMCID: PMC4995679 09/10/2016
  • Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. (Raj RV, Hari P, Pasquini M, Epperla N, D'Souza A, Fenske T, Shaw BE, Rizzo JD, Drobyski W, Hamadani M) Bone Marrow Transplant 2016 Dec;51(12):1602-1604 PMID: 27595288 09/07/2016
  • Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. (Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A) Biol Blood Marrow Transplant 2016 Oct;22(10):1893-1899 PMID: 27496215 PMCID: PMC5090978 08/09/2016
  • Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD? (Gallo S, Woolfrey AE, Burroughs LM, Storer BE, Flowers ME, Hari P, Pulsipher MA, Heimfeld S, Kiem HP, Sandmaier BM, Storb R) Bone Marrow Transplant 2016 Dec;51(12):1573-1578 PMID: 27479689 PMCID: PMC5143192 08/02/2016
  • Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. (Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, Horowitz MM, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M) Bone Marrow Transplant 2017 Jan;52(1):147-150 PMID: 27479688 08/02/2016
  • A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. (Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S) Bone Marrow Transplant 2017 Jan;52(1):59-65 PMID: 27427921 PMCID: PMC5215562 07/19/2016
  • Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins. (Franco DA, Truran S, Weissig V, Guzman-Villanueva D, Karamanova N, Senapati S, Burciu C, Ramirez-Alvarado M, Blancas-Mejia LM, Lindsay S, Hari P, Migrino RQ) J Am Heart Assoc 2016 Jun 13;5(6) PMID: 27412900 PMCID: PMC4937272 07/15/2016
  • Resistant or Sensitive: Time Is of the Essence: Response to Malek et al. (Hari P) Biol Blood Marrow Transplant 2016 Oct;22(10):1908 PMID: 27387038 07/09/2016
  • Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. (Dhakal B, Veltri LW, Fenske TS, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Esselman J, Watkins K, Pasquini MC, D'Souza A, Hari P, Kanate AS, Hamadani M) Biol Blood Marrow Transplant 2016 Oct;22(10):1773-1780 PMID: 27345140 06/28/2016
  • Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. (D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P) Br J Haematol 2017 Sep;178(5):816-819 PMID: 27292583 PMCID: PMC5154782 06/14/2016
  • Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. (Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M) J Clin Oncol 2016 Sep 10;34(26):3141-9 PMID: 27269951 PMCID: PMC5012706 06/09/2016
  • Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy. (Krishnan A, Vij R, Keller J, Dhakal B, Hari P) Am Soc Clin Oncol Educ Book 2016;35:210-21 PMID: 27249701 06/02/2016
  • Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 Jul;16(7):379-86 PMID: 27160644 05/11/2016
  • Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. (Rodriguez TE, Hari P, Stiff PJ, Smith SE, Sterrenberg D, Vesole DH) Biol Blood Marrow Transplant 2016 Aug;22(8):1391-1396 PMID: 27164062 PMCID: PMC5075527 05/11/2016
  • Mycobacterium mucogenicum bacteremia in immune-compromised patients, 2008-2013. (Abidi MZ, Ledeboer N, Banerjee A, Hari P) Diagn Microbiol Infect Dis 2016 Jun;85(2):182-5 PMID: 27117516 04/28/2016
  • Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. (Costa LJ, Hari PN, Kumar SK) Leuk Lymphoma 2016 Dec;57(12):2827-2832 PMID: 27104965 04/23/2016
  • DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation. (Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ) Case Rep Med 2016;2016:8503275 PMID: 26941799 PMCID: PMC4749780 03/05/2016
  • Morbidity and mortality attributable to Rothia bacteremia in neutropenic and nonneutropenic patients. (Abidi MZ, Ledeboer N, Banerjee A, Hari P) Diagn Microbiol Infect Dis 2016 May;85(1):116-20 PMID: 26906191 02/26/2016
  • Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. (van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A) Haematologica 2016 May;101(5):634-43 PMID: 26869630 PMCID: PMC5004373 02/13/2016
  • New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. (D'Souza A, Huang J, Hari P) Biol Blood Marrow Transplant 2016 Apr;22(4):768-770 PMID: 26743343 PMCID: PMC4801777 01/09/2016
  • Allogeneic stem cell transplantation for multiple myeloma: is there a future? (Dhakal B, Vesole DH, Hari PN) Bone Marrow Transplant 2016 Apr;51(4):492-500 PMID: 26726943 01/05/2016
  • Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940 01/05/2016
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. (Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V) Biol Blood Marrow Transplant 2016 Mar;22(3):432-40 PMID: 26493563 PMCID: PMC5030817 10/24/2015
  • Monocyte recovery at day 100 is associated with improved survival in multiple myeloma patients who undergo allogeneic hematopoietic cell transplantation. (Dhakal B, Brazauskas R, Lara CA, Hari P, Pasquini M, D'Souza A) Bone Marrow Transplant 2016 Feb;51(2):297-9 PMID: 26457907 PMCID: PMC4956087 10/13/2015
  • Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell products. (Zhu F, Heditke S, Kurtzberg J, Waters-Pick B, Hari P, Margolis DA, Keever-Taylor CA) Cytotherapy 2015 Dec;17(12):1813-9 PMID: 26454752 10/12/2015
  • Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. (Klyuchnikov E, Bacher U, Woo Ahn K, Carreras J, Kröger NM, Hari PN, Ku GH, Ayala E, Chen AI, Chen YB, Cohen JB, Freytes CO, Gale RP, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Martino R, Mussetti A, Savani BN, Schouten HC, Usmani SZ, Wiernik PH, Wirk B, Smith SM, Sureda A, Hamadani M) Bone Marrow Transplant 2016 Jan;51(1):58-66 PMID: 26437062 PMCID: PMC4703480 10/06/2015
  • American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. (Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E) Biol Blood Marrow Transplant 2015 Dec;21(12):2039-2051 PMID: 26428082 PMCID: PMC4757494 10/03/2015
  • Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. (Epperla N, Fenske TS, Hari PN, Hamadani M) World J Transplant 2015 Sep 24;5(3):81-8 PMID: 26421260 PMCID: PMC4580930 10/01/2015
  • Ibrutinib in Refractory Classic Hodgkin's Lymphoma. (Hamadani M, Balasubramanian S, Hari PN) N Engl J Med 2015 Oct;373(14):1381-2 PMID: 26422743 10/01/2015
  • Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. (D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P) J Clin Oncol 2015 Nov 10;33(32):3741-9 PMID: 26371138 PMCID: PMC4737858 09/16/2015
  • Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. (Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW) Biol Blood Marrow Transplant 2015 Nov;21(11):1883-7 PMID: 26371371 PMCID: PMC4604067 09/16/2015
  • Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach. (Cornell RF, Hari P, Drobyski WR) Biol Blood Marrow Transplant 2015 Dec;21(12):2061-2068 PMID: 26327628 PMCID: PMC4639405 09/04/2015
  • A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. (Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K) Biol Blood Marrow Transplant 2015 Dec;21(12):2100-2105 PMID: 26327631 09/04/2015
  • Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. (Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A) Bone Marrow Transplant 2015 Dec;50(12):1513-8 PMID: 26301967 PMCID: PMC4548821 08/25/2015
  • Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. (Hussain AS, Hari P, Brazauskas R, Arce-Lara C, Pasquini M, Hamadani M, D'Souza A) Am J Hematol 2015 Nov;90(11):E212-3 PMID: 26284951 PMCID: PMC4618044 08/19/2015
  • Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. (Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2015 Dec;21(12):2091-2099 PMID: 26253007 PMCID: PMC4639453 08/09/2015
  • Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. (Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG) Cancer 2015 Oct 15;121(20):3709-16 PMID: 26207349 PMCID: PMC4592381 07/25/2015
  • Minimal residual disease testing after stem cell transplantation for multiple myeloma. (Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF) Bone Marrow Transplant 2016 Jan;51(1):2-12 PMID: 26191950 07/21/2015
  • CYP2C19*17 genetic polymorphism--an uncommon cause of voriconazole treatment failure. (Abidi MZ, D'Souza A, Kuppalli K, Ledeboer N, Hari P) Diagn Microbiol Infect Dis 2015 Sep;83(1):46-8 PMID: 25986028 05/20/2015
  • Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 PMID: 25915809 04/29/2015
  • Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. (Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, Horowitz M, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS) Bone Marrow Transplant 2015 Jul;50(7):947-53 PMID: 25867651 PMCID: PMC4490016 04/14/2015
  • Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. (Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2015 Jul;21(7):1155-66 PMID: 25769794 03/15/2015
  • Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. (Dhakal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, Fenske T, Hari PN, Hamadani M) Bone Marrow Transplant 2015 Apr;50(4):610-2 PMID: 25621807 01/27/2015
  • New cancers after autotransplantations for multiple myeloma. (Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari PN) Biol Blood Marrow Transplant 2015 Apr;21(4):738-45 PMID: 25555448 PMCID: PMC4359647 01/04/2015
  • Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. (Costa LJ, Huang JX, Hari PN) Biol Blood Marrow Transplant 2015 Apr;21(4):701-6 PMID: 25555447 PMCID: PMC4361014 01/04/2015
  • Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. (Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG) Lancet Oncol 2014 Dec;15(13):1503-12 PMID: 25456369 12/03/2014
  • Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. (Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN) Biol Blood Marrow Transplant 2015 Feb;21(2):335-41 PMID: 25445028 PMCID: PMC4297511 12/03/2014
  • All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies. (Karmali R, Dalovisio A, Borgia JA, Venugopal P, Kim BW, Grant-Szymanski K, Hari P, Lazarus H) Blood Rev 2015 Mar;29(2):71-80 PMID: 25433571 12/01/2014
  • Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. (Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN) Bone Marrow Transplant 2015 Mar;50(3):449-51 PMID: 25387097 11/12/2014
  • Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. (Dhakal B, Strouse C, D'Souza A, Arce-Lara C, Esselman J, Eastwood D, Pasquini M, Saber W, Drobyski W, Rizzo JD, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2014 Dec;20(12):1926-31 PMID: 25111581 08/12/2014
  • A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. (Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher MA, Bethge WA, Chauncey TR, Lange T, Petersen FB, Hübel K, Woolfrey AE, Flowers ME, Storb R, Sandmaier BM) Haematologica 2014 Oct;99(10):1624-31 PMID: 25085357 PMCID: PMC4181260 08/03/2014
  • Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. (Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA, Freytes CO, Miller AM, Vose JM, Maziarz RT, Montoto S, Maloney DG, Hari PN) Bone Marrow Transplant 2014 Nov;49(11):1360-5 PMID: 25068422 PMCID: PMC4221526 07/30/2014
  • Older patients with myeloma derive similar benefit from autologous transplantation. (Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P) Biol Blood Marrow Transplant 2014 Nov;20(11):1796-803 PMID: 25046833 PMCID: PMC4194262 07/22/2014
  • Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. (Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen YB, Costa LJ, Fenske TS, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer EJ, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W, Alpdogan O, Cashen A, Dandoy C, Finke R, Gale R, Gibson J, Hsu JW, Janakiraman N, Laughlin MJ, Lill M, Cairo MS, Munker R, Rowlings PA, Schouten HC, Shea TC, Stiff PJ, Waller EK) Biol Blood Marrow Transplant 2014 Nov;20(11):1729-36 PMID: 25008330 PMCID: PMC4194275 07/11/2014
  • Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). (Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP) Haematologica 2014 Sep;99(9):1479-85 PMID: 24859879 PMCID: PMC4562537 05/27/2014
  • Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. (Michaelis LC, Hamadani M, Hari PN) Expert Rev Hematol 2014 Jun;7(3):321-4 PMID: 24785114 05/03/2014
  • Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions. (Kanate AS, Pasquini MC, Hari PN, Hamadani M) World J Stem Cells 2014 Apr 26;6(2):69-81 PMID: 24772235 PMCID: PMC3999783 04/29/2014
  • Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. (Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC, Resource for Clinical Investigation in Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2014 Aug;20(8):1183-9 PMID: 24769014 PMCID: PMC5036168 04/29/2014
  • Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. (Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS) Br J Haematol 2014 Aug;166(3):401-9 PMID: 24761838 04/26/2014
  • Incidence and outcomes of Clostridium difficile-associated disease in hematopoietic cell transplant recipients. (Guddati AK, Kumar G, Ahmed S, Ali M, Kumar N, Hari P, Venu N) Int J Hematol 2014 Jun;99(6):758-65 PMID: 24715522 04/10/2014
  • Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. (Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN) Biol Blood Marrow Transplant 2014 Mar;20(3):402-408.e1 PMID: 24342394 PMCID: PMC3961011 12/18/2013
  • Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. (Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN) J Clin Oncol 2014 Feb 01;32(4):273-81 PMID: 24344210 PMCID: PMC3897255 12/18/2013
  • Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. (Freytes CO, Vesole DH, LeRademacher J, Zhong X, Gale RP, Kyle RA, Reece DE, Gibson J, Schouten HC, McCarthy PL, Lonial S, Krishnan AY, Dispenzieri A, Hari PN) Bone Marrow Transplant 2014 Mar;49(3):416-21 PMID: 24270389 PMCID: PMC3947725 11/26/2013
  • Nanoliposomes protect against AL amyloid light chain protein-induced endothelial injury. (Truran S, Weissig V, Ramirez-Alvarado M, Franco DA, Burciu C, Georges J, Murarka S, Okoth WA, Schwab S, Hari P, Migrino RQ) J Liposome Res 2014 Mar;24(1):69-73 PMID: 24236475 PMCID: PMC3925072 11/19/2013
  • Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. (Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2014 Jan;20(1):89-97 PMID: 24161923 PMCID: PMC3886623 10/29/2013
  • Clinical and imaging predictors of 1-year and long-term mortality in light chain (AL) amyloidosis: a 5-year follow-up study. (Migrino RQ, Harmann L, Christenson R, Hari P) Heart Vessels 2014 Nov;29(6):793-800 PMID: 24141988 PMCID: PMC3992190 10/22/2013
  • Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. (Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG, Montoto S, Hari PN) Biol Blood Marrow Transplant 2013 Dec;19(12):1740-4 PMID: 24096096 PMCID: PMC3906436 10/08/2013
  • Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. (Avigan D, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Hsu KC) Biol Blood Marrow Transplant 2013 Dec;19(12):1661-9 PMID: 24018393 PMCID: PMC3914636 09/11/2013
  • Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. (Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, Kumar S, Nishihori T, Kindwall-Keller T, Saber W, Hari PN) Biol Blood Marrow Transplant 2013 Nov;19(11):1615-24 PMID: 23939198 PMCID: PMC3952066 08/14/2013
  • Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. (Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN) J Clin Oncol 2013 Sep 01;31(25):3100-9 PMID: 23897963 PMCID: PMC3753702 07/31/2013
  • Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. (Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN) Br J Haematol 2013 Sep;162(5):648-56 PMID: 23829536 PMCID: PMC3766698 07/09/2013
  • Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation. (Hari P, DeFor TE, Vesole DH, Bredeson CN, Burns LJ) Biol Blood Marrow Transplant 2013 Sep;19(9):1361-7 PMID: 23806773 06/29/2013
  • Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. (Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR) Biol Blood Marrow Transplant 2013 Sep;19(9):1368-73 PMID: 23806770 06/29/2013
  • Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. (Kornblit B, Maloney DG, Storb R, Storek J, Hari P, Vucinic V, Maziarz RT, Chauncey TR, Pulsipher MA, Bruno B, Petersen FB, Bethge WA, Hübel K, Bouvier ME, Fukuda T, Storer BE, Sandmaier BM) Biol Blood Marrow Transplant 2013 Sep;19(9):1340-7 PMID: 23769990 PMCID: PMC3755028 06/19/2013
  • Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era? (Chaudhary L, Kharfan-Dabaja MA, Hari P, Hamadani M) Bone Marrow Transplant 2013 Nov;48(12):1489-96 PMID: 23584438 04/16/2013
  • Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. (Bar M, Sandmaier BM, Inamoto Y, Bruno B, Hari P, Chauncey T, Martin PJ, Storb R, Maloney DG, Storer B, Flowers ME) Biol Blood Marrow Transplant 2013 Jun;19(6):949-57 PMID: 23523892 PMCID: PMC3846289 03/26/2013
  • Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. (Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM) J Clin Oncol 2013 Apr 20;31(12):1530-8 PMID: 23478054 PMCID: PMC3625710 03/13/2013
  • Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM) Biol Blood Marrow Transplant 2013 May;19(5):746-53 PMID: 23380340 PMCID: PMC3650915 02/06/2013
  • Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM) Biol Blood Marrow Transplant 2013 Apr;19(4):625-31 PMID: 23333532 PMCID: PMC3640440 01/22/2013
  • Multiple myeloma: future directions in autologous transplantation and novel agents. (Hari PN, McCarthy PL) Biol Blood Marrow Transplant 2013 Jan;19(1 Suppl):S20-5 PMID: 23290439 01/11/2013
  • Salvage second hematopoietic cell transplantation in myeloma. (Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2013 May;19(5):760-6 PMID: 23298856 PMCID: PMC3816739 01/10/2013
  • Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. (Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL) Biol Blood Marrow Transplant 2013 Feb;19(2):173-9 PMID: 23200705 PMCID: PMC3553321 12/04/2012
  • Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? (Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN, Lymphoma Working Committee of the CIBMTR) Blood 2012 Nov 15;120(20):4256-62 PMID: 23007405 PMCID: PMC3501720 09/26/2012
  • Protective role of clusterin in preserving endothelial function in AL amyloidosis. (Franco DA, Truran S, Burciu C, Gutterman DD, Maltagliati A, Weissig V, Hari P, Migrino RQ) Atherosclerosis 2012 Nov;225(1):220-3 PMID: 22981431 PMCID: PMC3478430 09/18/2012
  • Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. (Gupta V, Hari P, Hoffman R) Blood 2012 Aug 16;120(7):1367-79 PMID: 22700718 06/16/2012
  • Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. (Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM) J Clin Oncol 2012 Jul 10;30(20):2492-9 PMID: 22585697 PMCID: PMC4874149 05/16/2012
  • Lenalidomide after stem-cell transplantation for multiple myeloma. (McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C) N Engl J Med 2012 May 10;366(19):1770-81 PMID: 22571201 PMCID: PMC3744390 05/11/2012
  • Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. (Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV) Blood 2012 May 10;119(19):4375-82 PMID: 22422823 03/17/2012
  • Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy. (Vaughan J, Harrington AM, Hari PN, Kroft SH, Olteanu H) Am J Clin Pathol 2012 Mar;137(3):403-11 PMID: 22338052 02/18/2012
  • Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. (Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN) Biol Blood Marrow Transplant 2012 Aug;18(8):1255-64 PMID: 22198543 PMCID: PMC3376237 12/27/2011
  • Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. (Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, Freytes CO, Bolwell BJ, Hsu JW, Slavin S, Isola L, Rizzieri DA, Gale RP, Laport GG, Montoto S, Lazarus HM, Hari PN) Biol Blood Marrow Transplant 2012 Jul;18(7):1036-1043.e1 PMID: 22155506 PMCID: PMC3894923 12/14/2011
  • Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. (Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R) JAMA 2011 Nov 02;306(17):1874-83 PMID: 22045765 PMCID: PMC3217787 11/03/2011
  • Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. (Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Hari P) Leukemia 2012 May;26(5):1091-7 PMID: 22042147 PMCID: PMC3274611 11/02/2011
  • Percussion hemoglobinuria - a novel term for hand trauma-induced mechanical hemolysis: a case report. (Vasudev M, Bresnahan BA, Cohen EP, Hari PN, Hariharan S, Vasudev BS) J Med Case Rep 2011 Oct 07;5:508 PMID: 21982397 PMCID: PMC3213680 10/11/2011
  • Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. (Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG, Blood Marrow Transplant Clinical Trials Network (BMT CTN)) Lancet Oncol 2011 Dec;12(13):1195-203 PMID: 21962393 PMCID: PMC3611089 10/04/2011
  • Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. (Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, Timmons M, Motta A, Phillips SA, Hari P) Am J Physiol Heart Circ Physiol 2011 Dec;301(6):H2305-12 PMID: 21963839 PMCID: PMC3233808 10/04/2011
  • Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. (Ringdén O, Shrestha S, da Silva GT, Zhang MJ, Dispenzieri A, Remberger M, Kamble R, Freytes CO, Gale RP, Gibson J, Gupta V, Holmberg L, Lazarus H, McCarthy P, Meehan K, Schouten H, Milone GA, Lonial S, Hari PN) Bone Marrow Transplant 2012 Jun;47(6):831-7 PMID: 21946381 PMCID: PMC3369112 09/29/2011
  • Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. (Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ) Biol Blood Marrow Transplant 2012 May;18(5):690-7 PMID: 21875505 PMCID: PMC3762249 08/31/2011
  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. (Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, International Myeloma Working Group) Leukemia 2012 Jan;26(1):149-57 PMID: 21799510 PMCID: PMC4109061 07/30/2011
  • Detection of amyloid in abdominal fat pad aspirates in early amyloidosis: Role of electron microscopy and Congo red stained cell block sections. (Devata S, Hari P, Markelova N, Li R, Komorowski R, Shidham VB) Cytojournal 2011;8:11 PMID: 21760829 PMCID: PMC3132327 07/16/2011
  • Tocilizumab for the treatment of steroid refractory graft-versus-host disease. (Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Douglas Rizzo J, Saad A, Saber W, Hari P) Biol Blood Marrow Transplant 2011 Dec;17(12):1862-8 PMID: 21745454 PMCID: PMC3716013 07/13/2011
  • Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. (Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN) Blood 2011 Aug 18;118(7):1979-88 PMID: 21690560 PMCID: PMC3158724 06/22/2011
  • Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. (Vogl DT, Wang T, Pérez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P) Biol Blood Marrow Transplant 2011 Dec;17(12):1765-74 PMID: 21624486 PMCID: PMC3175301 06/01/2011
  • High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. (Olteanu H, Harrington AM, George B, Hari PN, Bredeson C, Kroft SH) Bone Marrow Transplant 2012 Mar;47(3):399-403 PMID: 21478917 04/12/2011
  • Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. (Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ) Biol Blood Marrow Transplant 2011 Sep;17(9):1343-51 PMID: 21320619 PMCID: PMC3150599 02/16/2011
  • CD200 expression in plasma cell myeloma. (Olteanu H, Harrington AM, Hari P, Kroft SH) Br J Haematol 2011 May;153(3):408-11 PMID: 21275968 02/01/2011
  • Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. (Reece DE, Vesole DH, Shrestha S, Zhang MJ, Pérez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN) Clin Lymphoma Myeloma Leuk 2010 Dec;10(6):458-63 PMID: 21156462 PMCID: PMC3370942 12/16/2010
  • Performing and processing FNA of anterior fat pad for amyloid. (Shidham VB, Hunt B, Jardeh SS, Barboi AC, Devata S, Hari P) J Vis Exp 2010 Oct 30(44) PMID: 21085098 PMCID: PMC3185617 11/19/2010
  • Access to hematopoietic stem cell transplantation: effect of race and sex. (Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, Majhail NS, Lee SJ, Horowitz MM) Cancer 2010 Jul 15;116(14):3469-76 PMID: 20564154 PMCID: PMC3153958 06/22/2010
  • Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. (Kumar SK, Flinn I, Noga SJ, Hari P, Rifkin R, Callander N, Bhandari M, Wolf JL, Gasparetto C, Krishnan A, Grosman D, Glass J, Sahovic EA, Shi H, Webb IJ, Richardson PG, Rajkumar SV) Leukemia 2010 Jul;24(7):1350-6 PMID: 20508619 PMCID: PMC2957585 05/29/2010
  • Light chain amyloidosis circa 2010: six prognostic markers and one sobering reality. (Migrino RQ, Hari P) J Am Soc Echocardiogr 2010 Jun;23(6):653-5 PMID: 20497862 05/26/2010
  • Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia. (Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P) Br J Haematol 2010 Aug;150(4):480-1 PMID: 20456357 05/12/2010
  • A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. (Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN) Biol Blood Marrow Transplant 2010 Jan;16(1):35-45 PMID: 20053330 PMCID: PMC2929576 01/08/2010
  • Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. (Hari PN, Majhail NS, Zhang MJ, Hassebroek A, Siddiqui F, Ballen K, Bashey A, Bird J, Freytes CO, Gibson J, Hale G, Holmberg L, Kamble R, Kyle RA, Lazarus HM, LeMaistre CF, Loberiza F, Maiolino A, McCarthy PL, Milone G, Omondi N, Reece DE, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee SJ, Rizzo JD, Mehta P) Biol Blood Marrow Transplant 2010 Mar;16(3):395-402 PMID: 19922808 PMCID: PMC2833344 11/20/2009
  • Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. (Migrino RQ, Mareedu RK, Eastwood D, Bowers M, Harmann L, Hari P) J Am Soc Echocardiogr 2009 Dec;22(12):1396-402 PMID: 19880277 PMCID: PMC2787973 11/03/2009
  • Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. (Harrington AM, Hari P, Kroft SH) Am J Clin Pathol 2009 Jul;132(1):60-6 PMID: 19864234 10/30/2009
  • Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. (Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM) Biol Blood Marrow Transplant 2009 Nov;15(11):1455-64 PMID: 19822306 PMCID: PMC2913553 10/14/2009
  • Phenotyping studies of clonotypic B lymphocytes from patients with multiple myeloma by flow cytometry. (Conway EJ, Wen J, Feng Y, Mo A, Huang WT, Keever-Taylor CA, Hari P, Vesole DH, Chang CC) Arch Pathol Lab Med 2009 Oct;133(10):1594-9 PMID: 19792049 10/02/2009
  • Systemic and microvascular oxidative stress induced by light chain amyloidosis. (Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA) Int J Cardiol 2010 Nov 05;145(1):67-8 PMID: 19446898 PMCID: PMC2974792 05/19/2009
  • Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up. (Migrino RQ, Christenson R, Szabo A, Bright M, Truran S, Hari P) BMC Med Phys 2009 May 05;9:5 PMID: 19416541 PMCID: PMC2686669 05/07/2009
  • Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. (van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN) Biol Blood Marrow Transplant 2009 May;15(5):554-63 PMID: 19361747 PMCID: PMC3120935 04/14/2009
  • Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. (Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D) Leukemia 2009 Aug;23(8):1528-34 PMID: 19322205 PMCID: PMC2726276 03/27/2009
  • Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. (Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P) Biol Blood Marrow Transplant 2009 Jan;15(1):109-17 PMID: 19135949 PMCID: PMC2929570 01/13/2009
  • Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. (Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P, Maziarz RT, Chauncey TR, Appelbaum FR, Sorror ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG) Blood 2009 Apr 02;113(14):3383-91 PMID: 19015394 PMCID: PMC2665904 11/19/2008
  • Case report: Delayed enhancement on cardiac MRI in a patient with multiple myeloma without amyloidosis. (Brahmbhatt T, Hari P, Cinquegrani M, Kumar N, Komorowski R, Migrino RQ) Br J Radiol 2008 Nov;81(971):e272-5 PMID: 18941041 10/23/2008
  • Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. (Kumar S, Pérez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P) Biol Blood Marrow Transplant 2008 Oct;14(10):1134-40 PMID: 18804043 PMCID: PMC2634851 09/23/2008
  • Comparison of twin and autologous transplants for multiple myeloma. (Bashey A, Pérez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee) Biol Blood Marrow Transplant 2008 Oct;14(10):1118-24 PMID: 18804041 PMCID: PMC2584240 09/23/2008
  • Nonmyeloablative conditioning for relapsed follicular lymphoma. (van Besien K, Hari P) Blood 2008 Sep 15;112(6):2585-6; author reply 2586-7 PMID: 18779408 09/10/2008
  • Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. (Drobyski WR, Hari P, Keever-Taylor C, Komorowski R, Grossman W) Bone Marrow Transplant 2009 Jan;43(2):169-77 PMID: 18762759 09/03/2008
  • Intraventricular dyssynchrony in light chain amyloidosis: a new mechanism of systolic dysfunction assessed by 3-dimensional echocardiography. (Migrino RQ, Harmann L, Woods T, Bright M, Truran S, Hari P) Cardiovasc Ultrasound 2008 Aug 07;6:40 PMID: 18687125 PMCID: PMC2525629 08/09/2008
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P) Biol Blood Marrow Transplant 2008 Aug;14(8):904-12 PMID: 18640574 PMCID: PMC3353768 07/22/2008
  • Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. (Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K) Biol Blood Marrow Transplant 2008 Feb;14(2):236-45 PMID: 18215784 PMCID: PMC2531158 01/25/2008
  • Multiple myeloma: charging toward a bright future. (Katzel JA, Hari P, Vesole DH) CA Cancer J Clin 2007 Sep-Oct;57(5):301-18 PMID: 17855486 09/15/2007
  • Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. (Surapaneni SN, Hari P, Knox J, Daniel J, Saeian K) Am J Gastroenterol 2007 Feb;102(2):449-51 PMID: 17100972 11/15/2006
  • New questions about transplantation in multiple myeloma. (Hari P, Pasquini MC, Vesole DH) Oncology (Williston Park) 2006 Sep;20(10):1230-42; discussion 1242, 1244, 1249-50 PMID: 17024872 10/10/2006
  • Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. (Anagnostopoulos A, Hari PN, Pérez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA) Biol Blood Marrow Transplant 2006 Aug;12(8):845-54 PMID: 16864055 07/26/2006
  • Reversible posterior leukoencephalopathy syndrome and bevacizumab. (Ozcan C, Wong SJ, Hari P) N Engl J Med 2006 Mar 02;354(9):980-2; discussion 980-2 PMID: 16514715 03/04/2006
  • Cure of multiple myeloma -- more hype, less reality. (Hari P, Pasquini MC, Vesole DH) Bone Marrow Transplant 2006 Jan;37(1):1-18 PMID: 16258534 11/01/2005
  • NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. (Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR) Blood 2006 Jan 15;107(2):827-34 PMID: 16174760 PMCID: PMC1895627 09/22/2005
  • Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity? (Hari P, Logan B, Drobyski WR) Biol Blood Marrow Transplant 2004 Nov;10(11):743-7 PMID: 15505605 10/27/2004
  • High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. (Hari P, Prasad Chemiti GK, Lankipalli RS) N Engl J Med 2000 Dec 28;343(26):1968-9 PMID: 11186673 02/24/2001
  • Mother-to-child HCV transmission. (Hari P, Prasad CG, Lankipalli R) Lancet 2001 Jan 13;357(9250):142; author reply 143 PMID: 11197421 02/24/2001
  • Last update: 08/17/2017
    jenkins-FCD Prod-141 f776ee82366dc5656a368d51cce32734d2f9b9a0